<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene S13I;W152C;L452R;D614G;L938F;K1191N literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.S13I;W152C;L452R;D614G;L938F;K1191N</span> literature reference collection</h1>
<div class="effect_section"><h2 id="vaccine_neutralization_efficacy">Vaccine neutralization efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster  were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed no significant CD4+ cell count effect for CAL.20C (B.1.429),  and a slight decrease in CD8+ percentage (p=0.0201) by Activation Induced Marker (AIM) assay (cellular immunity measurement).<br/>No signficant change in IF-gamma or IL-5 spot forming cell counts were observed. (<a href="https://doi.org/10.1101/2021.02.27.433180" class="lit_link">Tarke et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
